Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254599 | 1.00 | GABRA5 (0.47) | GABRA5GABRB2HSD17B10ACE2ACE | |
| SCHEMBL8250338 | 0.85 | MAPT (0.40) | ACE2ACEGRNSORT1ALDH1A1 | |
| SCHEMBL5870157 | 0.85 | MAPT (0.40) | ACE2ACEGRNSORT1ALDH1A1 | |
| SCHEMBL8249164 | 0.81 | KDM4E (0.50) | HSD17B10ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1690993 | 0.81 | KDM4E (0.50) | HSD17B10ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL8248710 | 0.79 | CTSK (0.43) | HSD17B10ACE2ACEALDH1A1MAPT | |
| SCHEMBL5869680 | 0.79 | CTSK (0.43) | HSD17B10ACE2ACEALDH1A1MAPT | |
| SCHEMBL5869777 | 0.78 | SHMT1 (0.41) | ACE2ACEALDH1A1MAPTNPC1 | |
| SCHEMBL5869659 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1NPC1RAB9A | |
| SCHEMBL5869648 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| JP-2002543120-A | — | — | 2002-12-17 | — | — | JP | claimed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | claimed |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | GABRA5 973/4885GABRB2 454/4885HSD17B10 592/4885 |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | GABRA5 3067/4885GABRB2 2800/4885HSD17B10 621/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | GABRA5 3067/4885GABRB2 2800/4885HSD17B10 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.